| DC73622 |
(S)-(-)-DQP-997-74 |
(S)-(-)-DQP-997-74 is a potent, selective GluN2C- and GluN2D-containing NMDARs negative allosteric modulator with IC50 of 69 and 35 nM, respectively, exhibits >100- and >300-fold over GluN2A- and GluN2B-containing receptors. |
|
| DC73623 |
DQP-997-74 |
DQP-997-74 is a potent, selective GluN2C- and GluN2D-containing NMDARs negative allosteric modulator with IC50 of 0.35 and 0.13 uM, respectively, exhibits >100-fold over GluN2A- and GluN2B-containing receptors. |
|
| DC73624 |
FP802
Featured
|
FP802 is a novel small molecule with significant neuroprotective properties, specifically designed to target and disrupt the TwinF interface within the NMDAR/TRPM4 death signaling complex. This unique mechanism allows FP802 to selectively eliminate extrasynaptic NMDAR (eNMDAR)-mediated toxicity, which is implicated in various neurodegenerative diseases, while preserving the essential physiological functions of synaptic NMDARs. This selectivity makes FP802 a promising therapeutic candidate for conditions involving excitotoxicity and neuronal cell death. |
|
| DC73625 |
GluN2A PAM (R)-9 |
GluN2A PAM (R)-9 is a potent, brain penetrant, GluN2A-selective positive allosteric modulator with EC50 of 0.51 uM, Emax 350%. |
|
| DC73626 |
Org 26576 |
Org 26576 (MK 8777. |
|
| DC73627 |
PTC-174 |
PTC-174 is a selective, positive allosteric modulator of NMDA receptors containing GluN2C or GluN2D subunits with EC50 of 4.1 uM (GluN1/2C) and 5.7 uM (GluN1/2D). |
|
| DC73628 |
UBP1700 |
UBP1700 is a subtype-selective competitive antagonist of GluN2C/2D-containing NMDA receptors with Ki of 7-9 nM, 50-fold selectivity over GluN2A and GluN2B. |
|
| DC73629 |
UBP791 |
UBP791 is a subtype-selective competitive antagonist of GluN2C/2D-containing NMDA receptors with Ki of 80-90 nM, 50-fold selectivity over GluN2A and GluN2B. |
|
| DC73630 |
UBP792 |
UBP792 is a novel negative allosteric modulator (antagonist) of NMDA receptors, displays partial subtype-selectivity by having a varied maximal inhibition of GluN2A-, GluN2B-, GluN2C-, and GluN2D-containing receptors (52%, 70%, 87%, 89%, respectively) wit |
|
| DC73631 |
ZCAN155 |
ZCAN155 is a small molecule that prevents AMPA-mediated excitotoxicity (IC50=35 nM) by targeting an allosteric binding site of AMPA glutamate receptor 2 (GluA2), restores neurological function and myelination. |
|
| DC73632 |
ZCAN262 |
ZCAN262 is a small molecule that prevents AMPA-mediated excitotoxicity (IC50=8.5 nM) by targeting an allosteric binding site of AMPA glutamate receptor 2 (GluA2). |
|
| DC73633 |
(S)-CE-123 |
(S)-CE-123 is a specific small molecule dopamine transporter (DAT) inhibitor, improves memory acquisition and memory retrieval. |
|
| DC73634 |
CDTP-32476 |
CDTP-32476 is a potent slow-onset dopamine reuptake blocker with an affinity of 8.6 nM, CDTP-32476 is moderately selective (14-fold) versus NE reuptake blockade with little effect on the SERT. |
|
| DC73635 |
D-578 |
D-578 is a potent, orally active triple monoamine reuptake inhibitor with Ki values of 16.2. 16.2, 3.23 nM, and 29.6, 20.6, 6.10 nM for the rat brain and cloned human dopamine, serotonin and norepinephrine transporters, respectively. |
|
| DC73636 |
FFN200 |
FFN200 is a vesicular monoamine transporter 2 (VMAT2) substrate, and the first probe to selectively trace monoamine exocytosis in both neuronal cell culture and brain tissue. |
|
| DC73637 |
GZ-11608 |
GZ-11608 is a potent and selective vesicular monoamine transporter-2 (VMAT2) inhibitor with Ki of 25 nM, GZ-11608 (EC50=620 nM) released vesicular dopamine 25-fold less potently than it inhibited VMAT2 dopamine uptake. |
|
| DC73638 |
GZ-794A |
GZ-794A is a potent, selective inhibitor of vesicular monoamine transporter-2 (VMAT2) with Ki of 30 nM, inhibits methamphetamine-evoked endogenous dopamine release with IC50 of 0.4 uM, shows potential for treatment for methamphetamine abuse. |
|
| DC73639 |
JJC8-016 |
JJC8-016 is a potent, Modafinil-derived dopamine transporter (DAT) ligand with Ki of 116 nM, attenuates compulsive-like methamphetamine self-administration in rats. |
|
| DC73640 |
JJC8-088 |
JJC8-088 is a potent, Modafinil-derived dopamine transporter (DAT) ligand with Ki of 2.53 nM. |
|
| DC73641 |
JJC8-091 |
JJC8-091 is a potent, Modafinil-derived dopamine transporter (DAT) ligand with Ki of 16.7 nM, attenuates compulsive-like methamphetamine self-administration in rats. |
|
| DC73642 |
LQFM215 |
LQFM215 (LQFM-215) is a synthetic L-proline transporter (PROT/SLC6A7) inhibitor, inhibits proline uptake in hippocampal synaptosome with IC50 of 20.4 uM, present neuroprotective potential. |
|
| DC73643 |
Lu AF60097 |
Lu AF60097 is a high affinity, allosteric inhibitor of serotonin transporter (SERT) inhibitor with IC50 of 31 nM for inhibition of [3H]IMI dissociation, targets the extracellular vestibule (S2 site). |
|
| DC73644 |
SRI-32743 |
SRI-32743 is a novel allosteric modulator of dopamine transporter (DAT), attenuates HIV-1 Tat protein-induced inhibition of the dopamine transporter. |
|
| DC73645 |
ZINC000006658090 |
ZINC000006658090 (Compound 8090) is a highly potent, selective and non-competitive inhibitor of serotonin transporter (SERT) with Ki of 14 nM. |
|
| DC73646 |
ZINC000443438219 |
ZINC000443438219 (Compound 8219) is a highly potent, selective and non-competitive inhibitor of serotonin transporter (SERT) with Ki of 3 nM. |
|
| DC73647 |
ABT-418 hydrochloride |
ABT-418 hydrochloride (ABT418) is an analog of (-)-nicotine and cholinergic ligand (activator) of nAChRs, a potent inhibitor of [3H]-cytisine binding to nAChR in rat brain with Ki of 2 nM. |
|
| DC73648 |
ABT-594 dihydrochloride |
Tebanicline dihydrochloride (ABT-594) is a potent, orally active neuronal nicotinic acetylcholine receptor (alpha 4 beta 2 nAChR) agonist with Ki of 37 pM (rat brain) and 55 pM (transfected human receptor). |
|
| DC73649 |
AN317 |
AN317 is a functionally selective, partial agonist of α6β2-containing nicotinic acetylcholine receptor (nAChR) with pEC50 of 7.17 (α6/α3β2β3V9'S receptor) in cell-based assays, inhibits the effect of nicotine with IC50 of 1.1 uM. |
|
| DC73650 |
AT1001 |
AT1001 (AT-1001) is a high affinity and selective α3β4 nAChR antagonist with Ki value of 2.4 nM, >90-fold selectivity over the other major subtypes (α4β2 and α7 nAChR). |
|
| DC73651 |
Cris-104 |
Cris-104 is a selective α4β2* neuronal nAChR agonist, demonstrates antinociceptive and antihypersensitivity in rodent acute/inflammatory and chronic pain models. |
|
